Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 170

Similar articles for PubMed (Select 22106827)

1.

Non-uptake of highly active antiretroviral therapy among patients with a CD4 count < 350 cells/μL in the UK.

Kober C, Johnson M, Fisher M, Hill T, Anderson J, Bansi L, Gompels M, Palfreeman A, Dunn D, Gazzard B, Gilson R, Post F, Phillips AN, Walsh J, Orkin C, Delpech V, Ainsworth J, Leen C, Sabin CA; UK Collaborative HIV Cohort (CHIC) Study.

HIV Med. 2012 Jan;13(1):73-8. doi: 10.1111/j.1468-1293.2011.00956.x. Epub 2011 Nov 22.

PMID:
22106827
2.

Time to viral load suppression in antiretroviral-naive and -experienced HIV-infected pregnant women on highly active antiretroviral therapy: implications for pregnant women presenting late in gestation.

Aziz N, Sokoloff A, Kornak J, Leva NV, Mendiola ML, Levison J, Feakins C, Shannon M, Cohan D.

BJOG. 2013 Nov;120(12):1534-47. doi: 10.1111/1471-0528.12226. Epub 2013 Aug 7.

PMID:
23924192
3.
4.

Responses to highly active antiretroviral therapy and clinical events in patients with a low CD4 cell count: late presenters vs. late starters.

Waters L, Fisher M, Anderson J, Wood C, Delpech V, Hill T, Walsh J, Orkin C, Bansi L, Gompels M, Phillips A, Johnson M, Gilson R, Easterbrook P, Leen C, Porter K, Gazzard B, Sabin C; UK CHIC Steering Committee.

HIV Med. 2011 May;12(5):289-98. doi: 10.1111/j.1468-1293.2010.00881.x. Epub 2010 Nov 3.

PMID:
21054749
5.
6.

The prognostic importance of changes in CD4+ cell count and HIV-1 RNA level in women after initiating highly active antiretroviral therapy.

Anastos K, Barrón Y, Cohen MH, Greenblatt RM, Minkoff H, Levine A, Young M, Gange SJ.

Ann Intern Med. 2004 Feb 17;140(4):256-64.

PMID:
14970148
7.

Comparison of prognostic importance of latest CD4+ cell count and HIV RNA levels in patients with advanced HIV infection on highly active antiretroviral therapy.

MacArthur RD, Perez G, Walmsley S, Baxter JD, Mullin CM, Neaton JD; Terry Beirn Community Programs for Clinical Research on AIDS (CPCRA) 042/045; Canadian HIV Trials Network (CTN) 102 Protocol Teams.

HIV Clin Trials. 2005 May-Jun;6(3):127-35.

PMID:
16192247
8.

A prospective study of highly active antiretroviral therapy in Indian human immunodeficiency virus positive patients.

Rajesh R, Vidyasagar S, Varma DM, Naik A, Hegde BM, Guddattu V, Kamath A.

Int J Risk Saf Med. 2013 Jan 1;25(1):53-65. doi: 10.3233/JRS-130580.

PMID:
23442298
9.
10.

HIV DNA and immune alteration during successful HAART.

Mamadou D, Yu-Huang Z, Xia C, Bo H, Hua-Ying Z, Yan H, Zi C, Qing L, Li-Wen Z, Mei H, Yun-Hai Y, Demba S, Aldebert D, Souleymane M.

Curr HIV Res. 2013 Jun;11(4):255-62.

PMID:
23822818
11.

Outcomes in the first year after initiation of first-line HAART among heterosexual men and women in the UK CHIC Study.

Barber TJ, Geretti AM, Anderson J, Schwenk A, Phillips AN, Bansi L, Gilson R, Hill T, Walsh J, Fisher M, Johnson M, Post F, Easterbrook P, Gazzard B, Palfreeman A, Orkin C, Leen C, Gompels M, Dunn D, Delpech V, Pillay D, Sabin CA; UK CHIC Study Steering Committee.

Antivir Ther. 2011;16(6):805-14. doi: 10.3851/IMP1818.

PMID:
21900712
12.
13.

Long-term CD4+ T-cell response to highly active antiretroviral therapy according to baseline CD4+ T-cell count.

García F, de Lazzari E, Plana M, Castro P, Mestre G, Nomdedeu M, Fumero E, Martínez E, Mallolas J, Blanco JL, Miró JM, Pumarola T, Gallart T, Gatell JM.

J Acquir Immune Defic Syndr. 2004 Jun 1;36(2):702-13.

PMID:
15167289
14.

Depression and clinical progression in HIV-infected drug users treated with highly active antiretroviral therapy.

Bouhnik AD, Préau M, Vincent E, Carrieri MP, Gallais H, Lepeu G, Gastaut JA, Moatti JP, Spire B; MANIF 2000 Study Group.

Antivir Ther. 2005;10(1):53-61.

PMID:
15751763
15.

Treatment interruption of highly active antiretroviral therapy in patients with nadir CD4 cell counts >200 cells/mm3.

Toulson AR, Harrigan R, Heath K, Yip B, Brumme ZL, Harris M, Hogg RS, Montaner JS.

J Infect Dis. 2005 Nov 15;192(10):1787-93. Epub 2005 Oct 5.

16.

CD4+ cell count, viral load, and highly active antiretroviral therapy use are independent predictors of body composition alterations in HIV-infected adults: a longitudinal study.

McDermott AY, Terrin N, Wanke C, Skinner S, Tchetgen E, Shevitz AH.

Clin Infect Dis. 2005 Dec 1;41(11):1662-70. Epub 2005 Oct 19.

17.

Factors influencing increases in CD4 cell counts of HIV-positive persons receiving long-term highly active antiretroviral therapy.

Smith CJ, Sabin CA, Youle MS, Kinloch-de Loes S, Lampe FC, Madge S, Cropley I, Johnson MA, Phillips AN.

J Infect Dis. 2004 Nov 15;190(10):1860-8. Epub 2004 Oct 8.

18.

Postpartum discontinuation of antiretroviral therapy and risk of maternal AIDS-defining events, non-AIDS-defining events, and mortality among a cohort of HIV-1-infected women in the United States.

Melekhin VV, Shepherd BE, Jenkins CA, Stinnette SE, Rebeiro PF, Bebawy SS, Rasbach DA, Hulgan T, Sterling TR.

AIDS Patient Care STDS. 2010 May;24(5):279-86. doi: 10.1089/apc.2009.0283.

19.

Prognostic value of plasma HIV RNA among highly active antiretroviral therapy users.

Tarwater PM, Gallant JE, Mellors JW, Gore ME, Phair JP, Detels R, Margolick JB, Muñoz A.

AIDS. 2004 Dec 3;18(18):2419-23.

PMID:
15622318
20.

Impact of injecting drug use on response to highly active antiretroviral treatment in HIV-1-infected patients: a nationwide population-based cohort study.

Larsen MV, Omland LH, Gerstoft J, Røge BT, Larsen CS, Pedersen G, Obel N, Kronborg G.

Scand J Infect Dis. 2010 Dec;42(11-12):917-23. doi: 10.3109/00365548.2010.511258. Epub 2010 Sep 15.

PMID:
20840000
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk